Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02883023
Other study ID # 58824
Secondary ID
Status Recruiting
Phase Phase 2
First received August 22, 2016
Last updated June 26, 2017
Start date November 2016
Est. completion date March 2018

Study information

Verified date June 2017
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Sophie E Horbach, MD
Phone 0031-20-5666679
Email s.e.horbach@amc.uva.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Capillary malformations (port-wine stains) consist of abnormally developed capillary blood vessels in the skin. To date, laser therapy is the only widely accepted treatment modality for capillary malformations, but this therapy has a suboptimal effect in approximately 50-60% of patients.

Intralesional bleomycin injections (sclerotherapy) are a common effective treatment option for vascular malformations with blood vessels with larger diameters. However, bleomycin cannot be injected adequately in the small sized vessels of capillary malformations. The use of an electric field over the tissue (electroporation) may solve this problem: it increases cell membrane permeability and therefore promotes localized delivery of drugs, within (endothelial) cells.

Electroporation in combination with bleomycin sclerotherapy ('electrosclerotherapy') may therefore offer new therapeutic options for capillary malformations. This proof of principle study aims to explore the effectiveness, safety and feasibility of this potential treatment option in a within-patient-controlled pilot study.


Description:

Capillary malformations are congenital abnormalities of the capillaries in the skin. These abnormally developed blood vessels cause a red color of the skin (also known as 'port-wine stain'),often in combination with a cobble-stone like aspect of the skin. Currently, the only widely accepted treatment option is laser therapy, in which the abnormal blood vessels are targeted with photocoagulation. However, in approximately 50-60% of patients, treatment outcome of laser therapy is suboptimal. Furthermore, re-darkening of the capillary malformation often occurs after laser therapy. Hence, there is a need for an alternative treatment option - especially for treatment-resistant and recurrent capillary malformations.

Intralesional bleomycin injections (sclerotherapy) are a common treatment option for vascular malformations of blood vessels and lymphatic vessels with a larger diameter (venous and lymphatic malformations). According to the literature, this treatment is effective in approximately 80-90% of patients. Unfortunately, the diameter of capillary blood vessels is too small, and therefore adequate localized injections of bleomycin are not possible in capillary malformations.

'Electroporation' is a physical phenomenon that causes an alteration of the structure of cell membranes through the exposure of cells to a short but intense electric field; this modification of the cell membrane increases its permeability. After electroporation, molecules that normally do not cross the cell membrane, either by diffusion or by active transport, can reach the intracellular environment. Therefore, electroporation is an ideal method for localized drug delivery, in particular for localized bleomycin delivery.

The combination of electroporation and bleomycin is already used in a variety of skin lesions, such as squamous cell carcinoma, with a surprisingly high rate of complete remission. Especially in vascular tumors, such as Kaposi sarcoma, there is an extremely high percentage of complete remission (90%), since the combination of bleomycin and electroporation causes a 'vascular lock' and intravascular thrombosis of tumor vascularization, leading to tumor regression.

This phenomenon (intravascular thrombosis and lesion regression) is exactly the intended effect of capillary malformation treatment.

The investigators therefore hypothesize that intralesional bleomycin injections combined with electroporation (electrosclerotherapy) can be an alternative treatment option for capillary malformations. This proof of principle study aims to explore the feasibility of this potential treatment option in a small patient sample.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with =1 completely or partially hypertrophic capillary malformation not exclusively located in the skin of the face, the skin overlying joints or in mucosal tissue

- Age = 18 years

- Fitzpatrick skin type 1-3 without evident sun tan

Exclusion Criteria:

- Pregnant or breastfeeding women

- Women with childbearing potential not using contraception

- Patients with chronic renal dysfunction of GFR <50 ml/minute

- Patients with chronic pulmonary dysfunction, active pulmonary infections or previous bleomycin lung toxicity

- Patients with ataxia teleangiectasia

- Patients with previous allergic reactions to bleomycin

- Patients who already received the maximum dose of bleomycin (400 mg or 400000 IU/m2)

- Patients with implanted electrical devices such as pacemakers or ICD's

- Patients with clinically manifested arrhythmia

- Patients with epilepsy

- Patients who are not able to return to the hospital for follow-up visits

- Patients who are likely not able to understand the terms and risks of the study (e.g. cognitive impairment)

Study Design


Intervention

Other:
Electrosclerotherapy
Combination of intralesional bleomycin sclerotherapy and electroporation
Drug:
Intralesional bleomycin injection
Local intralesional injections with bleomycin

Locations

Country Name City State
Netherlands Academic Medical Center (AMC) Amsterdam Noord-Holland

Sponsors (2)

Lead Sponsor Collaborator
Sophie Horbach IGEA

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient and Observer global assessment of capillary malformation (POSAS instrument) Change in patient and observer assessment of vascularity, pigmentation, thickness, pliability, relief, surface area and general opinion. 7 weeks
Secondary Adverse events Any adverse event or serious adverse event occurring after intervention 7 weeks
Secondary Colorimetry Change in color of capillary malformation in relation the contralateral healthy skin 7 weeks
Secondary Optical imaging (laser speckle imaging) Change in blood perfusion measured with non invasive imaging using light 7 weeks
See also
  Status Clinical Trial Phase
Completed NCT02561182 - Bone Health in Patients With Overgrowth
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Active, not recruiting NCT03987152 - Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life Phase 3
Recruiting NCT05113420 - The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
Recruiting NCT06189092 - Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study
Completed NCT04637997 - Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations N/A
Recruiting NCT06160739 - Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
Completed NCT02991352 - Stereotactic MRI Based Image Guidance for the Treatment of Vascular Malformations - a Pilot Study N/A
Recruiting NCT03972592 - Topical Sirolimus in Cutaneous Lymphatic Malformations Phase 2
Active, not recruiting NCT05418816 - SelfWrap-Assisted Arteriovenous Fistulas N/A
Recruiting NCT04104464 - Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)
Recruiting NCT02638389 - Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care Phase 3
Recruiting NCT03440827 - Development of a Specific Scale of Life'Quality for Children With Low-flow Vascular Malformations N/A
Recruiting NCT05563831 - National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Completed NCT00577213 - Diagnosis of Hemangiomas and Vascular Malformations N/A
Recruiting NCT05494710 - Bleomycin Electrosclerotherapy Treatment of Vascular Malformations: A Feasibility Study N/A
Enrolling by invitation NCT06399367 - Investigation of Lipedema, Lymphedema and Vascular Malformations by Multispectral Optoacoustic Tomography (MSOT)
Not yet recruiting NCT05983159 - A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Phase 2
Completed NCT01576601 - The Management of Postoperative Craniotomy Pain in Pediatric Patients N/A
Completed NCT04836884 - Vascular Anomaly Pathology and Genomics Biopsy Study N/A